These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21945484)

  • 21. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.
    McCormick PN; Kapur S; Seeman P; Wilson AA
    Nucl Med Biol; 2008 Jan; 35(1):11-7. PubMed ID: 18158938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography.
    Wilson AA; McCormick P; Kapur S; Willeit M; Garcia A; Hussey D; Houle S; Seeman P; Ginovart N
    J Med Chem; 2005 Jun; 48(12):4153-60. PubMed ID: 15943487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2'-iodospiperone.
    Leysen JE; Gommeren W; Mertens J; Luyten WH; Pauwels PJ; Ewert M; Seeburg P
    Psychopharmacology (Berl); 1993; 110(1-2):27-36. PubMed ID: 7870895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.
    Abi-Jaoude E; Segura B; Obeso I; Cho SS; Houle S; Lang AE; Rusjan P; Sandor P; Strafella AP
    Hum Brain Mapp; 2015 Jul; 36(7):2592-601. PubMed ID: 25788222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D₂/₃ receptors in their high-affinity state.
    van Wieringen JP; Shalgunov V; Janssen HM; Fransen PM; Janssen AG; Michel MC; Booij J; Elsinga PH
    J Med Chem; 2014 Jan; 57(2):391-410. PubMed ID: 24325578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.
    Bonaventura J; Navarro G; Casadó-Anguera V; Azdad K; Rea W; Moreno E; Brugarolas M; Mallol J; Canela EI; Lluís C; Cortés A; Volkow ND; Schiffmann SN; Ferré S; Casadó V
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3609-18. PubMed ID: 26100888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural Investigation of the Dopamine-2 Receptor Agonist Bromocriptine Binding to Dimeric D2
    Salmas RE; Seeman P; Stein M; Durdagi S
    J Chem Inf Model; 2018 Apr; 58(4):826-836. PubMed ID: 29537837
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute cocaine treatment enhances the antagonistic allosteric adenosine A2A-dopamine D2 receptor-receptor interactions in rat dorsal striatum without increasing significantly extracellular dopamine levels.
    Romero-Fernandez W; Zhou Z; Beggiato S; Wydra K; Filip M; Tanganelli S; Borroto-Escuela DO; Ferraro L; Fuxe K
    Pharmacol Rep; 2020 Apr; 72(2):332-339. PubMed ID: 32124388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies.
    Mach RH; Luedtke RR
    J Labelled Comp Radiopharm; 2018 Mar; 61(3):291-298. PubMed ID: 28857231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain.
    Otsuka T; Ito H; Halldin C; Takahashi H; Takano H; Arakawa R; Okumura M; Kodaka F; Miyoshi M; Sekine M; Seki C; Nakao R; Suzuki K; Finnema S; Hirayasu Y; Suhara T; Farde L
    J Nucl Med; 2009 May; 50(5):703-10. PubMed ID: 19372485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.
    Suridjan I; Rusjan P; Addington J; Wilson AA; Houle S; Mizrahi R
    J Psychiatry Neurosci; 2013 Mar; 38(2):98-106. PubMed ID: 23010256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist.
    Sánchez-Soto M; Bonifazi A; Cai NS; Ellenberger MP; Newman AH; Ferré S; Yano H
    Mol Pharmacol; 2016 Apr; 89(4):457-66. PubMed ID: 26843180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding Interactions of Dopamine and Apomorphine in D2High and D2Low States of Human Dopamine D2 Receptor Using Computational and Experimental Techniques.
    Durdagi S; Salmas RE; Stein M; Yurtsever M; Seeman P
    ACS Chem Neurosci; 2016 Feb; 7(2):185-95. PubMed ID: 26645629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.
    Narendran R; Hwang DR; Slifstein M; Talbot PS; Erritzoe D; Huang Y; Cooper TB; Martinez D; Kegeles LS; Abi-Dargham A; Laruelle M
    Synapse; 2004 Jun; 52(3):188-208. PubMed ID: 15065219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO.
    Willeit M; Ginovart N; Kapur S; Houle S; Hussey D; Seeman P; Wilson AA
    Biol Psychiatry; 2006 Mar; 59(5):389-94. PubMed ID: 16373068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of discrimination by agonists for D2 and D3 dopamine receptors.
    Burris KD; Pacheco MA; Filtz TM; Kung MP; Kung HF; Molinoff PB
    Neuropsychopharmacology; 1995 Jul; 12(4):335-45. PubMed ID: 7576010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET radiotracer development for imaging high-affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine-18 labeled aminotetralins in rodents.
    Mukherjee J; Majji D; Kaur J; Constantinescu CC; Narayanan TK; Shi B; Nour MT; Pan ML
    Synapse; 2017 Mar; 71(3):. PubMed ID: 27864853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist (11)C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate.
    Mukherjee J; Narayanan TK; Christian BT; Shi B; Dunigan KA; Mantil J
    Synapse; 2000 Jul; 37(1):64-70. PubMed ID: 10842352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.